Diiodothyronine.

Type 1, 2 and 3 deiodinases all require selenocysteine to strip iodine atoms from the thyronine ring, and diiodothyronine is generated by exactly that sequence of reactions. Low selenium status impairs deiodinase activity, which is settled biochemistry rather than an inference. This describes how the body makes diiodothyronine and is not a claim that supplemental selenium raises it.

Iodide is trapped by the thyroid, oxidised, and attached to tyrosine residues on thyroglobulin to give monoiodotyrosine and diiodotyrosine, which couple to form T4 and T3. Diiodothyronine arises downstream when deiodinases remove further iodine atoms. Without adequate iodine none of it proceeds, though excess iodine has its own consequences and more is not better here.

Thyroid peroxidase needs its heme prosthetic group to catalyse iodide oxidation and coupling, so low iron status limits hormone synthesis upstream of any deiodination step. This is why iron status is examined alongside thyroid measures. Iron also interferes with the absorption of orally taken thyroid hormone when the two are swallowed together, which is a separate and opposite consideration.

Iodination occurs on tyrosine residues within the thyroglobulin protein rather than on free tyrosine, so supplemental free tyrosine does not straightforwardly feed the pathway. The structural relationship is real, the practical relationship is much weaker than supplement marketing suggests. Dietary protein supplies far more tyrosine than the thyroid pathway consumes.

Thyroid hormone receptors use zinc finger domains to bind DNA, so zinc status touches the response side of the axis rather than hormone synthesis. Deiodinase activity has also been reported to be lower in zinc-deficient states. This matters for people with genuinely low zinc status and says little for anyone already replete.

Calcium carbonate is a documented cause of reduced levothyroxine absorption when taken at the same time, and separating the doses by several hours is the standard handling. Any orally administered iodothyronine is subject to the same physical chemistry. This is an interaction to plan around rather than a reason to avoid either substance.

Ferrous sulfate taken alongside thyroid hormone measurably reduces its absorption, which is why prescribing guidance separates them in time. The same binding chemistry applies to iodothyronines generally. Note the direction is opposite to iron's supportive role in hormone synthesis, so both statements are true at once and the difference is timing.

Studies of levothyroxine absorption show a measurable reduction when the dose is taken with coffee rather than water, with the effect attributed to binding or to accelerated transit. Separating the two by roughly an hour restores absorption. The finding was established for levothyroxine, and applying it to other orally taken iodothyronines is an extension rather than a direct result.

Thyroid hormone receptors bind DNA as heterodimers with RXR, and 9-cis retinoic acid is the RXR ligand, so the two nuclear receptor systems are physically coupled at the level of gene transcription. This is textbook nuclear receptor biology. It describes signalling architecture and does not mean vitamin A supplements change thyroid hormone levels.

Trials of standardised ashwagandha root extract have reported increases in T3 and T4 and decreases in TSH in some participants. Adding it on top of an exogenous iodothyronine pushes the same axis in the same direction from two places. This one belongs in a caution box rather than a stack suggestion, and it is a conversation for a prescriber.